Meeting
2013 ASCO Annual Meeting
A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG.
Authors
Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, Australia
Danny Rischin , Daniela Matei , Jeffrey C. Goh , Michelle Margaret Vaughan , Philip James Beale , Meaghan Elizabeth Tenney , Julie Martyn , Dirkje Willemien Sommeijer , Jose Luis Iglesias , David C. Bibby , Jeremy Simpson , Elizabeth E. Doolin , Corinne E. Williams , Martin R. Stockler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01624493
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS5612)
DOI
10.1200/jco.2013.31.15_suppl.tps5612
Abstract #
TPS5612
Poster Bd #
55B
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
First Author: Fabian Trillsch
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.
First Author: Paul Swiecicki
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2016 ASCO Annual Meeting
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
First Author: Beverly Long